-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KjfoALEFdsR1fKgv85CbWxPSIFxGUeNr0TkAbSiRAfmUB79eeXGRhwrFayDHJ+RI rNq5HGnuhas7tzdUoKeRjw== 0000950123-95-002822.txt : 19951010 0000950123-95-002822.hdr.sgml : 19951010 ACCESSION NUMBER: 0000950123-95-002822 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19951006 SROS: NASD GROUP MEMBERS: JOHNSON & JOHNSON DEVELOPMENT CORP. GROUP MEMBERS: JOHNSON & JOHNSON ET AL SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: AMYLIN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000881464 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330266089 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-42168 FILM NUMBER: 95579073 BUSINESS ADDRESS: STREET 1: 9373 TOWNE CENTRE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6195522200 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON ET AL CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 9085240400 SC 13D 1 SCHEDULE 13D 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. )* AMYLIN PHARMACEUTICALS, INC. ---------------------------- (Name of Issuer) COMMON STOCK, $.001 par value ------------------------------ (Title of Class of Securities) 032346108 -------------- (CUSIP Number) Peter S. Galloway, Esq. Associate General Counsel Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933 (908) 524-2484 -------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) September 27, 1995 ------------------ (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box / /. Check the following box if a fee is being paid with the statement /X/. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.) NOTE: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 2 SCHEDULE 13D CUSIP NO. 032346108 PAGE 2 OF 11 PAGES --------- ----- ---- - ------------------------------------------------------------------------------------------------------------------------------------ 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Johnson & Johnson 22-1024240 - ------------------------------------------------------------------------------------------------------------------------------------ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) / / (B) / / - ------------------------------------------------------------------------------------------------------------------------------------ 3 SEC USE ONLY - ------------------------------------------------------------------------------------------------------------------------------------ 4 SOURCE OF FUNDS* - ------------------------------------------------------------------------------------------------------------------------------------ 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) / / - ------------------------------------------------------------------------------------------------------------------------------------ 6 CITIZENSHIP OR PLACE OF ORGANIZATION New Jersey - ------------------------------------------------------------------------------------------------------------------------------------ 7 SOLE VOTING POWER -0- NUMBER OF ------------------------------------------------------------------------------------------------------------ SHARES 8 SHARED VOTING POWER BENEFICIALLY OWNED BY EACH 1,893,868 REPORTING ------------------------------------------------------------------------------------------------------------ PERSON 9 SOLE DISPOSITIVE POWER WITH -0- ------------------------------------------------------------------------------------------------------------ 10 SHARED DISPOSITIVE POWER 1,893,868 - ------------------------------------------------------------------------------------------------------------------------------------ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,893,868 - ------------------------------------------------------------------------------------------------------------------------------------ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / / - ------------------------------------------------------------------------------------------------------------------------------------ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 6.78% - ------------------------------------------------------------------------------------------------------------------------------------ 14 TYPE OF REPORTING PERSON* CO - ------------------------------------------------------------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. 3 SCHEDULE 13D CUSIP NO. 032346108 PAGE 3 OF 11 PAGES --------- ----- ---- - ------------------------------------------------------------------------------------------------------------------------------------ 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Johnson & Johnson Development Corporation 22-2007317 - ------------------------------------------------------------------------------------------------------------------------------------ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) / / (B) / / - ------------------------------------------------------------------------------------------------------------------------------------ 3 SEC USE ONLY - ------------------------------------------------------------------------------------------------------------------------------------ 4 SOURCE OF FUNDS* - ------------------------------------------------------------------------------------------------------------------------------------ 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) / / - ------------------------------------------------------------------------------------------------------------------------------------ 6 CITIZENSHIP OR PLACE OF ORGANIZATION New Jersey - ------------------------------------------------------------------------------------------------------------------------------------ 7 SOLE VOTING POWER -0- NUMBER OF ------------------------------------------------------------------------------------------------------------ SHARES 8 SHARED VOTING POWER BENEFICIALLY OWNED BY EACH 1,893,868 REPORTING ------------------------------------------------------------------------------------------------------------ PERSON 9 SOLE DISPOSITIVE POWER WITH -0- ------------------------------------------------------------------------------------------------------------ 10 SHARED DISPOSITIVE POWER 1,893,868 - ------------------------------------------------------------------------------------------------------------------------------------ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,893,868 - ------------------------------------------------------------------------------------------------------------------------------------ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / / - ------------------------------------------------------------------------------------------------------------------------------------ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 6.78% - ------------------------------------------------------------------------------------------------------------------------------------ 14 TYPE OF REPORTING PERSON* CO - ------------------------------------------------------------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. 4 Page 4 of 11 pages Item 1. Security and Issuer: Common Stock, $.001 par value ("Common Stock") Amylin Pharmaceuticals, Inc. 9373 Towne Centre Drive San Diego, California 92121 Item 2. Identity and Background: (a) Johnson & Johnson ("J&J") and Johnson & Johnson Development Corporation ("JJDC"), both New Jersey corporations (b) One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 (c) The principal business of J&J is health care products. JJDC is a wholly-owned subsidiary of J&J engaged in the venture capital business. The name, citizenship, residence or business address and principal occupation or employment (and the name, principal business and address of any corporation or other organization in which such employment is conducted) of each director and executive officer of J&J and JJDC is set forth on Appendix A hereto. (d),(e) To the best of J&J's knowledge, neither J&J nor any of its directors or executive officers has, during the past five years: (i) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. To the best of JJDC's knowledge, neither JJDC nor any of its directors or executive officers has, during the past five years: (i) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, 5 Page 5 of 11 pages decree or final order prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (f) Not applicable. Item 3. Source and Amount of Funds or Other Consideration: On June 20, 1995, JJDC purchased from Amylin Pharmaceuticals, Inc. (the "Company") 724,638 shares of Common Stock of the Company for $5.0 million. On September 27, 1995, JJDC purchased from the Company 1,169,230 shares of Common Stock of the Company for $9.5 million. No funds were borrowed to finance either purchase. Item 4. Purpose of Transaction: On June 20, 1995, the Company and Lifescan, Inc., a wholly-owned subsidiary of J&J, entered into a Collaboration Agreement to develop and commercialize the Company's lead drug candidate, pramlintide (the "Collaboration"). In conjunction with the Collaboration Agreement, the Company also entered into a Stock Purchase Agreement with JJDC and a Loan and Security Agreement with J&J. In accordance with the terms of the Stock Purchase Agreement, JJDC purchased 724,638 shares of Common Stock for $5.0 million. Subject to the terms of the Stock Purchase Agreement, the Company has the right to sell additional shares of Common Stock to JJDC in an aggregate amount of $10.0 million prior to the first milestone of the Collaboration. Pursuant to such right, on September 27, 1995, JJDC purchased 1,169,230 shares from the Company for $9.5 million. The sale of an additional $500,000 (61,539) of shares of Common Stock to JJDC by the Company is subject to the approval of the U.S. Federal Trade Commission pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Upon the achievement of certain additional milestones, the Company also has the right to sell additional shares of its Common Stock to JJDC for net proceeds of up to $30 million. 6 Page 6 of 11 pages Pursuant to the terms of the Loan and Security Agreement, the Company has agreed to issue to J&J warrants (the "Warrants") to purchase 50,000 shares of Common Stock, at an exercise price of $12.00 per share and with a ten-year exercise period, for each $1.0 million principal amount of each Development Loan (as defined in the Loan and Security Agreement) loaned to the Company thereunder. As of the October 5, 1995, no Development Loans had been made under the Loan and Security Agreement. Pursuant to the terms of the Stock Purchase Agreement, JJDC has agreed that, until June 2005, or sooner in the event that the Collaboration Agreement is terminated, it will not acquire any additional securities of the Company other than pursuant to the Stock Purchase Agreement or upon exercise of the Warrants. Such restriction shall terminate upon the occurrence of a change in control of the Company or certain other events, as described more fully in the Stock Purchase Agreement. JJDC has also agreed not to sell, transfer or dispose of any shares of Common Stock for certain time periods, as set forth more fully in the Stock Purchase Agreement. Item 5. Interest in Securities of the Issuer: As of October 5, 1995, J&J and JJDC each had beneficial ownership of an aggregate of 1,893,868 shares of Common Stock. Based upon the shares of Common Stock outstanding as of June 30, 1995, as reported in the Company's Amendment No. 1 on Form 10-Q/A for the quarter ended June 30, 1995, and the shares of Common Stock offered pursuant to the Company's Prospectus dated September 22, 1995, 1,893,868 shares constitute approximately 6.78% of the outstanding shares of Common Stock. Item 6. Contracts, Arrangements, etc.: The shares of Common Stock were purchased by JJDC pursuant to a Stock Purchase Agreement dated June 20, 1995 between the Company and JJDC. 7 Page 7 of 11 pages Item 7. Exhibits: Exhibit 7.1 - Stock Purchase Agreement dated June 20, 1995 between the Company and JJDC (incorporated by reference to Exhibit 10.26 to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 1995 and by reference to Exhibit 10.26(a) to the Company's Amendment No. 1 on Form 10-Q/A for the fiscal quarter ended June 30, 1995). Exhibit 7.2 - Loan and Security Agreement dated June 20, 1995 between the Company and J&J (incorporated by reference to Exhibit 10.27 to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 1995). 8 Page 8 of 11 pages SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. JOHNSON & JOHNSON DEVELOPMENT CORPORATION By: /s/ B.M. Flicker ------------------- B.M. Flicker Secretary Date: October 6, 1995 JOHNSON & JOHNSON By: /s/ P.S. Galloway ------------------- P.S. Galloway Secretary Date: October 6, 1995 9 CUSIP 032346108 Page 9 of 11 Pages APPENDIX A Board of Directors and Executive Officers of Johnson & Johnson The directors and executive officers of Johnson & Johnson are identified in the table below. Directors of Johnson & Johnson are indicated by an asterisk.
NAME BUSINESS ADDRESS CITIZENSHIP PRINCIPAL OCCUPATION ---- ---------------- ----------- -------------------- 1 . Professor Sir James Black(*) The James Black Foundation United Kingdom Professor and Head of the 68 Half Moon Lane Department of Analytical Dulwich, London SE249JE Pharmacology at the Rayne England Institute, King's College School of Medicine, Chairman of the James Black Foundation 2 . Dr. Gerard N. Burrow(*) Yale New Haven School of United States Dean of the Yale University Medicine School of Medicine since 1992 333 Cedar Street New Haven, CT 06510 3 . Joan Ganz Cooney(*) Children's Television Workshop United States Chairman, Children's Television One Lincoln Plaza Workshop New York, NY 10023 4. James G. Cullen BellAtlantic Corporation United States Vice Chairman 1310 North Court House Road Bell Atlantic Corporation Arlington, VA 22201 5. Roger S. Fine Johnson & Johnson United States Corporate Vice President, One Johnson & Johnson Plaza Administration, and Member, New Brunswick, NJ 08933 Executive Committee of Johnson & Johnson 6 . George S. Frazza Johnson & Johnson United States Vice President and General One Johnson & Johnson Plaza Counsel and Member, Executive New Brunswick, NJ 08933 Committee of Johnson & Johnson 7 . Ronald G. Gelbman Johnson & Johnson United States Member, Executive Committee of One Johnson & Johnson Plaza Johnson & Johnson New Brunswick, NJ 08933 8. Philip M. Hawley(*) Philip M. Hawley United States Former Chairman and Chief Suite 2280 Executive Officer of Carter 444 South Flower Street Hawley Hale Stores, Inc. Los Angeles, CA 90071-2900 9. Clark H. Johnson(*) Johnson & Johnson United States Member, Executive Committee and One Johnson & Johnson Plaza Vice President, Finance of New Brunswick, NJ 08933 Johnson & Johnson 10. Ann Dibble Jordan(*) Johnson & Johnson United States Director of various other One Johnson & Johnson Plaza corporations New Brunswick, NJ 08933 11. Christian A. Koffmann Johnson & Johnson France Member, Executive Committee of One Johnson & Johnson Plaza Johnson & Johnson New Brunswick, NJ 08933 12. Arnold G. Langbo(*) 111 Capital Avenue, S.W. Canada Chairman of the Board and Chief Battle Creek, MI 49015 Executive Officer of the Kellogg Company
10 CUSIP 032346108 Page 10 of 11 Pages
NAME BUSINESS ADDRESS CITIZENSHIP PRINCIPAL OCCUPATION ---- ---------------- ----------- -------------------- 13. Ralph S. Larsen(*) Johnson & Johnson United States Chairman, Board of Directors, One Johnson & Johnson Plaza Chief Executive Officer and New Brunswick, NJ 08933 Chairman, Executive Committee, of Johnson & Johnson 14. James T. Lenehan Johnson & Johnson United States Member, Executive Committee of One Johnson & Johnson Plaza Johnson & Johnson New Brunswick, NJ 08933 15. Dr. John S. Mayo(*) AT&T Bell Laboratories, Inc. United States President, Emeritus, AT&T Bell 600 Mountain Avenue Laboratories, Inc. Murray Hill, NJ 07974 16. Thomas S. Murphy(*) Capital Cities/ABC, Inc. United States Chairman of the Board and Chief 77 West 66th Street Executive Officer of Capital New York, NY 10023-6298 Cities/ABC 17. Paul J. Rizzo (*) IBM Corporation United States Retired Vice Chairman of Old Orchard Road International Business Machines Armonk, NY 10504 Corporation 18. Maxine F. Singer, Ph.D.(*) Carnegie Institution of United States President of the Carnegie Washington Institution of Washington 1530 P Street, N.W. Washington, D.C. 20005-1910 19. Roger B. Smith (*) United States Retired Chairman of General Johnson & Johnson Motors Corporation, Member of the One Johnson & Johnson Plaza Business Council and Trustee of New Brunswick NJ 08933 the Alfred P. Sloan Foundation 20. Robert N. Wilson(*) Johnson & Johnson United States Vice Chairman, Board of Directors One Johnson & Johnson Plaza and Vice Chairman, Executive New Brunswick, NJ 08933 Committee of Johnson & Johnson
11 CUSIP 032346108 Page 11 of 11 Pages BOARD OF DIRECTORS AND EXECUTIVE OFFICERS OF JOHNSON & JOHNSON DEVELOPMENT CORPORATION The directors and executive officers of Johnson & Johnson Development Corporation are identified in the table below. Directors of Johnson & Johnson Development Corporation are indicated by an asterisk.
NAME BUSINESS ADDRESS CITIZENSHIP PRINCIPAL OCCUPATION ---- ---------------- ----------- -------------------- 1. William L. Brower, Jr.(*) McNeil Consumer Products United States Vice President Finance, Company McNeil Consumer Products Camp Hill Road Company Fort Washington, PA 19034 2. Blair M. Flicker(*) Johnson & Johnson United States General Attorney of Johnson & One Johnson & Johnson Plaza Johnson and Secretary of New Brunswick, NJ 08933 Johnson & Johnson Development Corporation 3. Peter S. Galloway Johnson & Johnson United States Secretary and Associate One Johnson & Johnson Plaza General Counsel of Johnson & New Brunswick, NJ 08933 Johnson 4. Dr. Robert Gussin(*) Johnson & Johnson United States Vice President, Science and One Johnson & Johnson Plaza Technology of Johnson & New Brunswick, NJ 08933 Johnson 5. Edward J. Hartnett(*) Johnson & Johnson United States Company Group Chairman, One Johnson & Johnson Plaza Johnson & Johnson New Brunswick, NJ 08933 6. Susan Lambert(*) Johnson & Johnson United Vice President of One Johnson & Johnson Plaza Kingdom Johnson & Johnson Development New Brunswick, NJ 08933 Corporation 7. Ting Pau Oei(*) Johnson & Johnson United States Vice President of One Johnson & Johnson Plaza Johnson & Johnson Development New Brunswick, NJ 08933 Corporation 8. Peter T. Tattle(*) Johnson & Johnson Canada Company Group Chairman, One Johnson & Johnson Plaza Johnson & Johnson New Brunswick, NJ 08933 9. James R. Utaski(*) Johnson & Johnson United States Corporate Vice President, One Johnson & Johnson Plaza Business Development of New Brunswick, NJ 08933 Johnson & Johnson; President of Johnson & Johnson Development Corporation 10. Dr. Brad Vale(*) Johnson & Johnson United States Vice President of One Johnson & Johnson Plaza Johnson & Johnson Development New Brunswick, NJ 08933 Corporation
-----END PRIVACY-ENHANCED MESSAGE-----